Centrifugation and filtration prepare body fluid samples for downstream measurement by helping organize the material before microscopy, immunoassays, flow cytometry, or nucleic acid testing. These preparation steps matter because the quality and form of the processed sample influence which cellular, biochemical, or molecular features can be examined. In cancer research, this supports evaluation of abnormal cells, proteins, metabolites, or circulating tumor DNA.
Each assay provides a different type of evidence. Microscopy supports visual examination of abnormal cells, whereas immunoassays measure proteins and flow cytometry analyzes cellular features. Nucleic acid testing adds molecular information, including circulating tumor DNA. Selecting among these approaches, or combining them, allows studies to target evidence relevant to cancer detection, classification, treatment monitoring, or disease progression.
Circulating tumor DNA adds a molecular readout to measurements based on cells, proteins, or metabolites. Its detection through nucleic acid testing can therefore contribute to identifying cancer-related changes in a fluid sample. Within cancer research, this information supports liquid biopsy investigations and may help develop personalized diagnostic strategies alongside other analytical measurements.
A typical workflow begins with a collected fluid sample, followed by preparation steps such as centrifugation and filtration. The processed material is then examined using microscopy, immunoassays, flow cytometry, or nucleic acid testing. Researchers interpret the resulting cellular, biochemical, or molecular measurements in relation to cancer detection, classification, treatment monitoring, or disease progression.
Cancer studies can use measured abnormalities in cells, proteins, metabolites, or circulating tumor DNA for several purposes. The same general analytical framework may support detection, help classify disease, monitor responses during treatment, or evaluate progression. The specific outcome depends on which features are measured and which method, such as microscopy or molecular testing, is applied.
Because body fluid collection is often minimally invasive, researchers can investigate cancer-related cellular, biochemical, and molecular signals without relying solely on more invasive sampling approaches. This characteristic supports liquid biopsy research, while the resulting measurements can contribute to personalized diagnostic strategies. Blood, urine, cerebrospinal fluid, and ascites are among the fluid types examined in these studies.